Gilead acquires biotechnology company Ouro for up to $2.2 billion

```htmlGolden Ten Data, March 24｜Gilead Sciences announced that it has signed a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing therapies for autoimmune diseases. Gilead will pay a $1.675 billion upfront cash consideration (subject to customary adjustments), plus up to $500 million in potential milestone payments. This transaction adds OM336 (gamgertamig) to Gilead’s inflammation portfolio, a BCMAxCD3 T cell engager currently in clinical development. In ongoing phase 1/2 clinical studies, the drug has demonstrated efficacy in severe autoimmune diseases, including autoimmune hemolytic anemia and immune thrombocytopenia. OM336 has received Fast Track and Orphan Drug designations.```